Predictive Value of Serum CTRP9 and AMH on IVF-ET Assisted Pregnancy Outcome in Patients With Polycystic Ovary Syndrome
Objective To explore the predictive value of serum complement C1q/tumour necrosis factor-related protein 9(CTRP9)and anti-millenarian hormone(AMH)on pregnancy outcome of in vitro fertilization and embryo transfer(IVF-ET)in patients with polycystic ovary syndrome(PCOS).Methods A total of 85 PCOS patients who underwent IVF-ET at fertility centre,the First Affiliated Hospital of Chongqing Medical University were selected.They were divided into 43 cases in the clinical pregnancy group and 42 cases in the non-pregnant group according to the pregnancy outcome.The general data of the two groups were recorded,and serum CTRP9 and A levels were measured to analyze their relationship with pregnancy outcome.Results The serum CTRP9 and AMH levels in the non-pregnant group were(290.19±58.97)ng/mL and 3.39(2.09,5.42)ng/mL,which were lower than those of the pregnant group(413.63±89.56)ng/mL,7.42(5.45,9.90)ng/mL(P＜0.05).Serum CTRP9,AMH level and number of eugenic embryos are protective factors for successful IVF-ET pregnancy in patients with PCOS(P＜0.05).The sensitivity and specificity of serum CTRP9 in predicting pregnancy success in PCOS patients undergoing IVF-ET was 74.40%and 90.50%,with an AUC(Area under the curve,AUC)of 0.836,while serum AMH predicted sensitivity and specificity of 83.70%and 73.80%,with an AUC of 0.859.The sensitivity and specificity of combined serum CTRP9 and AMH prediction were 88.40%and 92.90%,respectively,with an area under thecurve of 0.924,which was higher than the value of CTRP9 or AMH prediction alone.Conclusion Serum CTRP9 and AMH are strongly associated with IVF-ET outcomes in patients with PCOS and are independent influences on pregnancy outcomes,and the combination of these two tests improves the predictive value compared with single-indicator tests.
万方数据
维普
